Autosomal dominant polycystic kidney disease: time for a change?
Diagnosis and treatment of autosomal dominant polycystic kidney disease (ADPKD) is rapidly changing. Cellular pathways that involve the polycystins are being mapped and involve the primary cilium, intracellular calcium and cAMP regulation, and the mammalian target of rapamycin (mTOR) pathway. With the use of new imaging approaches, earlier diagnosis of hepatic cystic disease is possible, and measurement of kidney and cystic growth as well as kidney blood flow is possible over relatively short periods. PKD gene type, gender, proteinuria, and the presence of hypertension relate to the rate of kidney growth in ADPKD. On the basis of risk factors for progression to ESRD and the pathogenic roles that intracellular cAMP and mTOR play in cystogenesis, novel therapies are now being tested, including maximal inhibition of the renin-angiotensin system, inhibition of renal intracellular cAMP using vasopressin V2 receptor antagonists, and somatostatin analogues, as well as inhibitors of mTOR. This review addresses the current understanding of the pathogenesis and the natural history of ADPKD; accuracy and reliability of diagnostic approaches in utero, childhood, and adulthood; the value of reliable magnetic resonance imaging to measure disease progression early in the course of ADPKD; and novel therapeutic approaches that are being evaluated in ADPKD.
Chapman
Arlene B
AB
Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA. arlene.chapman@emoryhealthcare.org
D003560:Cysts / Q000473:pathology; D018450:Disease Progression; D042241:Early Diagnosis; D006801:Humans; D007668:Kidney / Q000473:pathology; D025202:Molecular Diagnostic Techniques / Q000379:methods; D009929:Organ Size; D016891:Polycystic Kidney, Autosomal Dominant / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D014463:Ultrasonography / Q000379:methods